

## iGene inks personalised medicine project with Eli Lilly in Singapore

19 November 2020 | News

**iGene will perform genotyping analysis as part of LCCP's research screening activities.**

INEX Innovate's iGene Laboratory (iGene) has announced a project with Eli Lilly and Company's research unit Lilly Centre for Clinical Pharmacology (LCCP), which conducts early phase clinical trials in healthy participants and patients in Singapore.

Under this collaboration, iGene will perform genotyping analysis as part of LCCP's research screening activities.

Genotyping is a technology that detects variations at specific positions in the human DNA sequence. This variation – the genotype – occurs naturally and is considered a genetic fingerprint of any individual. It is identified as distinct compared to a reference sequence derived from the general population or a defined subgroup, and can differ from the reference sequence in numerous ways. Genotyping has a vast range of uses across scientific and medical research.

"We are delighted to assist LCCP in identifying suitable volunteers to participate in clinical trials. This partnership is a testament to iGene's deep scientific capability in the field of molecular diagnostics and evidence of constant advancement in Singapore's cutting edge biotech ecosystem. As such, we're excited to be a part of LCCP's efforts in clinical research," said Kane Black, Chief Executive of iGene Laboratory and INEX Innovate.

*Image Caption- From left to right: Dr. Chia-Pin Chang - Vice President of Research & Development, Kane Black - Chief Executive, Dr. Sherry Ho - Laboratory Director*